First-Time Generics Of Sanofi-Aventis’ Arava Enter Market
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA appears to have denied Sanofi’s March citizen petition requesting refusal to approve ANDAs without certain bioequivalence studies.
You may also be interested in...
Was Apokyn Safety Update A Missed Opportunity For Supernus To Hold Off Generic Refill Cartridge?
US FDA told the company to add a warning to the label in late January, about a month before the generic refill cartridge was approved.
Arava, Avandia's Divergent Paths: FDA Strengthens Arava Label Warning
As FDA advisory committee debated the fate of Avandia, the agency bolsters liver warning on Arava, another drug David Graham suggested be removed from the market.
Arava, Avandia's Divergent Paths: FDA Strengthens Arava Label Warning
As FDA advisory committee debated the fate of Avandia, the agency bolsters liver warning on Arava, another drug David Graham suggested be removed from the market.